S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
S&P 500   4,431.85 (+2.43%)
DOW   34,725.47 (+1.65%)
QQQ   351.80 (+3.14%)
AAPL   170.33 (+6.98%)
MSFT   308.26 (+2.81%)
FB   301.71 (+2.40%)
GOOGL   2,667.02 (+3.37%)
AMZN   2,879.56 (+3.11%)
TSLA   846.35 (+2.08%)
NVDA   228.40 (+4.08%)
BABA   115.23 (+3.08%)
NIO   20.90 (-0.99%)
AMD   105.24 (+2.57%)
CGC   7.27 (+6.13%)
MU   79.27 (+0.70%)
GE   92.10 (+2.45%)
T   25.21 (+4.52%)
F   19.54 (-0.05%)
DIS   138.63 (+2.37%)
AMC   15.06 (+3.72%)
PFE   54.33 (+1.80%)
ACB   3.91 (+3.17%)
BA   190.57 (+0.43%)
NASDAQ:PBYI

Puma Biotechnology Stock Competitors

$2.28
+0.03 (+1.33%)
(As of 01/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.17
$2.29
50-Day Range
$2.25
$3.58
52-Week Range
$2.17
$14.14
Volume
374,307 shs
Average Volume
805,437 shs
Market Capitalization
$93.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.93

Puma Biotechnology (NASDAQ:PBYI) Vs. AADI, TSVT, BDSI, DYN, VRNA, SPRO, MRNS, XLO, OMER, and THRX

Should you be buying Puma Biotechnology stock or one of its competitors? The main competitors of Puma Biotechnology include Aadi Bioscience (AADI), 2seventy bio (TSVT), BioDelivery Sciences International (BDSI), Dyne Therapeutics (DYN), Verona Pharma (VRNA), Spero Therapeutics (SPRO), Marinus Pharmaceuticals (MRNS), Xilio Therapeutics (XLO), Omeros (OMER), and Theseus Pharmaceuticals (THRX). These companies are all part of the "pharmaceutical preparations" industry.

Puma Biotechnology vs.

2seventy bio (NASDAQ:TSVT) and Puma Biotechnology (NASDAQ:PBYI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.

Puma Biotechnology has a consensus price target of $10.00, suggesting a potential upside of 338.60%. Given Puma Biotechnology's higher probable upside, analysts plainly believe Puma Biotechnology is more favorable than 2seventy bio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
2seventy bio
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Puma Biotechnology
1 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.25

In the previous week, 2seventy bio's average media sentiment score of 0.00 equaled Puma Biotechnology's average media sentiment score.

Company Overall Sentiment
2seventy bio Neutral
Puma Biotechnology Neutral

2seventy bio has a net margin of 0.00% compared to Puma Biotechnology's net margin of -19.29%. 2seventy bio's return on equity of 0.00% beat Puma Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
2seventy bio N/A N/A N/A
Puma Biotechnology -19.29% -665.45% -19.53%

85.4% of Puma Biotechnology shares are owned by institutional investors. 19.5% of Puma Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Puma Biotechnology received 509 more outperform votes than 2seventy bio when rated by MarketBeat users. However, 100.00% of users gave 2seventy bio an outperform vote while only 66.49% of users gave Puma Biotechnology an outperform vote.

CompanyUnderperformOutperform
2seventy bioOutperform Votes
1
100.00%
Underperform Votes
No Votes
Puma BiotechnologyOutperform Votes
510
66.49%
Underperform Votes
257
33.51%

2seventy bio has higher earnings, but lower revenue than Puma Biotechnology.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
2seventy bioN/AN/AN/AN/AN/A
Puma Biotechnology$225.10 million0.41-$59.99 million-$1.20-1.90

Summary

2seventy bio beats Puma Biotechnology on 6 of the 11 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBYI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment >-1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

Puma Biotechnology (NASDAQ:PBYI) vs. Its Competitors

TypePuma BiotechnologyPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$93.22M$5.74B$4.61B$6.91B
Dividend YieldN/A2.55%2.08%2.84%
P/E Ratio-1.9013.4216.4518.09
Price / Sales0.41464.415,476.99220.05
Price / CashN/A163.8261.1868.55
Price / Book-15.208.137.258.51
Net Income-$59.99M$99.84M$99.15M$156.58M
7 Day Performance-5.00%-2.44%-3.22%-2.14%
1 Month Performance-26.92%-17.95%-15.26%-12.08%
1 Year Performance-80.65%-33.91%-22.59%-8.36%

Puma Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
AADI
Aadi Bioscience
1.7532 of 5 stars
$17.79
+4.3%
$47.50
+167.0%
+104.5%$371.70M$15M-1.3312Analyst Downgrade
TSVT
2seventy bio
1.2917 of 5 stars
$15.75
+6.4%
N/AN/A$368.06MN/A0.00N/AGap Up
High Trading Volume
BDSI
BioDelivery Sciences International
2.9583 of 5 stars
$3.66
+0.0%
$6.92
+89.0%
-4.7%$361.59M$156.47M11.81176
DYN
Dyne Therapeutics
1.3515 of 5 stars
$7.00
+2.3%
N/A-62.8%$360.70MN/A-2.7547
VRNA
Verona Pharma
2.2 of 5 stars
$5.98
+0.0%
$21.00
+251.2%
-20.9%$359.02MN/A-4.0726Analyst Report
Short Interest ↓
SPRO
Spero Therapeutics
2.2664 of 5 stars
$11.09
+2.8%
$55.00
+395.9%
-36.6%$358.47M$9.33M-4.1589Positive News
MRNS
Marinus Pharmaceuticals
2.1181 of 5 stars
$9.75
+3.3%
$32.60
+234.4%
-26.0%$358.47M$1.72M-3.9569Analyst Revision
XLO
Xilio Therapeutics
2.3583 of 5 stars
$13.42
+6.6%
$31.50
+134.7%
N/A$357.86MN/A0.002,021Short Interest ↓
OMER
Omeros
1.7864 of 5 stars
$5.63
+4.8%
$29.50
+424.0%
-71.5%$352.11M$73.81M-2.83277
THRX
Theseus Pharmaceuticals
2.4917 of 5 stars
$8.99
+2.7%
$25.00
+178.1%
N/A$347.94MN/A0.002,021Positive News
GBIO
Generation Bio
2.2498 of 5 stars
$6.11
+3.9%
$30.25
+395.1%
-77.5%$347.72MN/A-2.91100Analyst Downgrade
NATR
Nature's Sunshine Products
1.8598 of 5 stars
$17.59
+0.9%
$24.00
+36.4%
+9.6%$347.60M$385.20M16.75837Positive News
ALLK
Allakos
2.5265 of 5 stars
$6.39
+3.0%
$90.36
+1,314.1%
-95.2%$347.06MN/A-1.55125
AVDL
Avadel Pharmaceuticals
1.8448 of 5 stars
$5.91
+7.6%
$16.00
+170.7%
-30.0%$346.44M$22.33M-5.232,020Analyst Downgrade
Analyst Revision
RYTM
Rhythm Pharmaceuticals
1.8131 of 5 stars
$6.89
+2.0%
$33.83
+391.0%
-78.3%$346.35MN/A-5.3490News Coverage
KVSA
Khosla Ventures Acquisition
0.3333 of 5 stars
$9.72
+0.0%
N/AN/A$344.96MN/A0.00N/AShort Interest ↓
News Coverage
GERN
Geron
1.7998 of 5 stars
$1.07
+5.6%
$5.50
+414.0%
-41.6%$344.49M$250K-3.2454Gap Up
ORIC
ORIC Pharmaceuticals
2.4248 of 5 stars
$8.70
+9.4%
$26.33
+202.7%
-69.7%$342.62MN/A-3.7361News Coverage
High Trading Volume
ABUS
Arbutus Biopharma
1.9314 of 5 stars
$2.53
+4.3%
$6.90
+172.7%
-35.3%$342.23M$6.91M-2.7877Short Interest ↓
AMTI
Applied Molecular Transport
2.825 of 5 stars
$8.77
+8.7%
$80.33
+816.0%
-76.4%$337.56MN/A-3.8880News Coverage
RDUS
Radius Health
2.1514 of 5 stars
$7.10
+4.6%
$13.00
+83.1%
-65.2%$336.13M$238.65M-4.38310
AKBA
Akebia Therapeutics
1.8581 of 5 stars
$1.91
+4.2%
$9.00
+371.2%
-47.6%$334.17M$295.31M-1.01380Gap Up
VACC
Vaccitech
2.1583 of 5 stars
$9.35
+2.8%
$24.33
+160.2%
N/A$326.12M$4.82M0.002,021Gap Down
ORMP
Oramed Pharmaceuticals
1.8667 of 5 stars
$8.48
+3.4%
$35.67
+320.6%
+18.0%$324.65M$2.70M-11.0112
XBIT
XBiotech
1.4583 of 5 stars
$10.46
+1.6%
N/A-43.0%$317.97M$40K-24.3391News Coverage
MRSN
Mersana Therapeutics
1.7481 of 5 stars
$4.32
+0.5%
$25.25
+484.5%
-76.7%$310.66M$830K-2.02110
ACIU
AC Immune
1.6781 of 5 stars
$4.24
+3.1%
$15.50
+265.6%
-30.2%$308.05M$16.46M-3.93137Analyst Upgrade
Analyst Revision
Positive News
VTGN
VistaGen Therapeutics
1.9931 of 5 stars
$1.54
+7.8%
$7.50
+387.0%
-33.0%$307.54M$1.09M-4.0521Gap Up
NKTX
Nkarta
2.3981 of 5 stars
$9.31
+4.0%
$64.83
+596.4%
-79.6%$306.76M$120K-3.7595
ADAG
Adagene
1.6598 of 5 stars
$6.96
+0.3%
$32.39
+365.4%
N/A$303.30M$700K0.002,020News Coverage
High Trading Volume
IMUX
Immunic
2.1181 of 5 stars
$11.27
+2.7%
$48.40
+329.5%
-31.9%$295.83MN/A-3.0728Short Interest ↓
TRDA
Entrada Therapeutics
2.0464 of 5 stars
$9.31
+10.1%
$29.00
+211.5%
N/A$290.59MN/A0.002,021
ANNX
Annexon
1.7581 of 5 stars
$7.53
+7.0%
$39.00
+417.9%
-68.8%$288.96MN/A-2.4848Negative News
THTX
Theratechnologies
1.0981 of 5 stars
$3.02
+1.3%
$2.00
+33.8%
+38.5%$287.27M$66.05M-9.7454
CTMX
CytomX Therapeutics
1.9664 of 5 stars
$4.40
+5.0%
$12.80
+190.9%
-39.8%$287.10M$100.36M-3.61145
KALV
KalVista Pharmaceuticals
1.8531 of 5 stars
$11.72
+4.4%
$52.83
+350.8%
-26.8%$286.79M$12.69M-4.3956
ALT
Altimmune
2.0333 of 5 stars
$7.20
+9.3%
$29.71
+312.7%
-52.0%$286.12M$8.19M-3.6743Analyst Downgrade
VKTX
Viking Therapeutics
1.8667 of 5 stars
$3.58
+1.7%
$16.00
+346.9%
-53.8%$280.08MN/A-5.0419News Coverage
PYXS
Pyxis Oncology
2.0848 of 5 stars
$8.41
+1.2%
$20.00
+137.8%
N/A$275.55MN/A0.002,021Short Interest ↓
SELB
Selecta Biosciences
2.5265 of 5 stars
$2.36
+5.1%
$6.90
+192.4%
-46.4%$275.29M$16.60M-4.5444Short Interest ↑
COGT
Cogent Biosciences
1.9664 of 5 stars
$6.70
+1.3%
$25.50
+280.6%
-29.3%$267.00M$7.87M-0.9215
NBTX
Nanobiotix
0.7998 of 5 stars
$7.64
+0.7%
N/A-56.4%$266.07M$2.87M0.0089Short Interest ↑
News Coverage
KMDA
Kamada
0.7998 of 5 stars
$5.95
+0.5%
N/A-9.1%$264.89M$133.25M59.51408Analyst Downgrade
News Coverage
PRVB
Provention Bio
2.2456 of 5 stars
$4.16
+18.3%
$17.75
+326.7%
-75.3%$263.64MN/A-2.0959Options Volume
News Coverage
Gap Up
High Trading Volume
VSTM
Verastem
2.2314 of 5 stars
$1.44
+1.4%
$6.33
+339.8%
-25.7%$262.35M$88.52M-3.2749
PRQR
ProQR Therapeutics
1.9131 of 5 stars
$5.20
+3.3%
$26.14
+402.7%
-1.2%$261.07M$10.80M-4.481,504Short Interest ↑
IMRX
Immuneering
1.8248 of 5 stars
$10.00
+6.1%
$36.25
+262.5%
N/A$259.41MN/A0.002,021Lockup Expiration
News Coverage
High Trading Volume
STTK
Shattuck Labs
2.3782 of 5 stars
$6.13
+1.1%
$47.00
+666.7%
-86.9%$258.97M$9.93M-3.9359
THRN
Thorne Healthtech
2.0348 of 5 stars
$4.90
+3.7%
$11.50
+134.7%
N/A$257.47M$138.46M0.002,021Short Interest ↑
CLVS
Clovis Oncology
2.0148 of 5 stars
$1.93
+5.2%
$6.88
+256.2%
-77.0%$250.86M$164.52M-0.68N/A
This page was last updated on 1/28/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.